Jason Field

Part of SolutionInc Technologies Ltd., SolutionInc Ltd. provides conferencing wifi network solutions for any facility size. SolutionInc is based in Halifax, CA and was acquired by SolutionInc Technologies Ltd. on June 28, 2002 for $15.38 million. The Canadian company's network services help venues attract conferences and meetings by providing a reliable and robust wifi network that exceeds their expectations. The CEO of the company is Glen Lavigne.

Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Noble Denton Group Ltd. provides marine & offshore engineering and consultancy services. It provides technical service to the oil and gas industry and help to design, build, install and operate oil and gas onshore, maritime and offshore assets to ensure safety, and sustainability. The company was founded in 1904 and is headquartered in London, the United Kingdom.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel.

Innovative Medicines Canada manufactures medical and toilet products. The company was founded on April 23, 1914 and is headquartered in Ottawa, Canada.

Saskatchewan Indian Institute of Technologies offers certificate and diploma programs in the areas of trades and industrial, business and technology. It programs include trades and industrial, business and technology, health and community studies and adult basic education. The company was founded in 1976 and is headquartered in Saskatoon, Canada.

Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

Bedside Clinical Systems, Inc. develops Responses to Illness Severity Quantification (RISQ) framework severity of illness clinical decision support for frontline healthcare professionals, hospital administrators and quality managers. It provides BedsidePEWS, that uses the RISQ framework to empower frontline clinicians who care for hospitalized children. The company was founded by Christopher Parshuram in March 2011 and is headquartered in Toronto, Canada.

Clinical Trials Ontario operates as a research and development company for various diseases. The company was founded in 2012 and is headquartered in Toronto, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

Encycle Therapeutics, Inc. provides biotechnology services. It offers rapid synthesis of drug-like macrocycles or membrane-permeable nacellins which have enormous potential to target intracellular protein-protein interactions. The company was founded by Andrei Yudin is headquartered in Toronto, Canada.

Triphase Accelerator Corp. develops oncology drug therapeutics. It engages in accelerating oncology products from pre-investigational new drug (pre-IND) to Phase I/Phase II POC. The firm?s product includes Marizomib which is used in cancer treatment. The company is headquartered in Toronto, Canada.

QD Solar, Inc. develops photovoltaic cells using colloidal quantum dot technology in Canada. Its quantum dot technology combines silicon solar cells with infrared solar cells in a hybrid architecture to harvest more of the solar spectrum than silicon alone. The company was founded by Sjoerd Hoogland and Edward Hartley Sargent in 2014 and is headquartered in Toronto, Canada.

Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety.

Amplitude Ventures is a venture capital firm. The firm was founded in 2018. It’s headquartered in Montreal, Canada.

Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA.

Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada.

Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then.

Congruence Therapeutics, Inc. operates as a Canadian biotechnology company. The company is based in Westmount, Canada. Congruence Therapeutics was founded in 2021 by Clarissa Desjardins, who has been the CEO since 2021.